Company: APM
Filing Date: 2025-12-05
Form Type: 424B5
Source: 0001213900-25-118752
Chunk: 310

Company: Aptorum Group Ltd
Filing Date: 2025-12-05
Form: 424B5
Chunk 310
---
.) 09/01/2019 – 02/28/2020

Title: Brain-enriched microRNAs detectable in
plasma as biomarkers of Alzheimer’s disease.

Alzheimer’s Drug Discovery Foundation.
Ref #: 201809-2016425 11/11/2019 – 11/10/2020

Title: Circulating brain-enriched microRNAs as
peripheral biomarkers of neurodegeneration.

<div align='center'>177</div>

The main goal of this project is to assess associations
between circulating brain-enriched microRNAs and known AD markers in preclinical AD samples from A4 prevention study.

NIH/NIA SBIR Phase II Grant Number 2R44AG044860-02
02/15/2015 – 01/31/2017

Title: Early detection of Alzheimer’s (MCI
stage): Analysis of plasma cell-free miRNA.

The goal of this Phase II study was to provide
further validation for the MCI microRNA signature using plasma samples from well-characterized heterogeneous cohorts and to define microRNA
biomarker signatures for predicting AD “progressors” and for differentiating AD from other neurodegenerative diseases.

NIH/NIA SBIR Phase I Grant Number 1R43AG053116-01
06/01/2016 – 11/30/2016

Title: Circulating organ-enriched microRNAs as
biomarkers of aging

The goal of this study was to analyze brain-enriched
microRNA signatures detectable in plasma in the context of normal aging; the study was conducted in collaboration with the New York
Blood Center.

Rett Syndrome Research Trust (2014 and 2015 awards)
12/01/2014 – 04/30/2016

Title: Analysis of circulating brain-enriched
microRNAs as biomarkers for Rett Syndrome.

The goal of this study was to assess brain-enriched
microRNA biomarkers in plasma samples of Mecp2 deficient male and female mice and controls.

NIH/NIA SBIR Phase I Grant Number 1R43AG044860-01
07/01/2013 – 12/31/2013

Title: Early detection of Alzheimer’s disease
at MCI stage by analysis of cell-free miRNA in plasma.

The goal of this study was to assess feasibility
of detecting MCI patients who would progress to AD dementia and